Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.40 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | F12 | P00748 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7774527 | 0.92 | MEN1 (0.43) | CYP2C19SMN1; SMN2HSD17B10ATMCACNA1B | |
| SCHEMBL7772734 | 0.89 | SMN1; SMN2 (0.44) | CYP2C19SMN1; SMN2CACNA1BBIRC2ALDH1A1 | |
| SCHEMBL7105883 | 0.89 | HSD17B10 (0.45) | HSD17B10ATMCACNA1BBIRC2GPR119 | |
| SCHEMBL7768806 | 0.88 | SMN1; SMN2 (0.43) | CYP2C19SMN1; SMN2CACNA1BBIRC2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL7772776 | 0.87 | SMN1; SMN2 (0.45) | CYP2C19SMN1; SMN2CACNA1BBIRC2ALDH1A1 | |
| SCHEMBL6363547 | 0.87 | CYP2C19 (0.44) | CYP2C19SMN1; SMN2GPR119ALDH1A1CYP2D6 | |
| SCHEMBL5116971 | 0.87 | SMN1; SMN2 (0.45) | CYP2C19SMN1; SMN2GPR119ALDH1A1CYP2D6 | |
| SCHEMBL7772730 | 0.86 | SMN1; SMN2 (0.43) | CYP2C19SMN1; SMN2CACNA1BBIRC2ALDH1A1 | |
| SCHEMBL7774847 | 0.85 | SMN1; SMN2 (0.46) | CYP2C19SMN1; SMN2ALDH1A1CYP2D6CYP2C9 | |
| SCHEMBL6362903 | 0.83 | SMN1; SMN2 (0.44) | CYP2C19SMN1; SMN2CACNA1BALDH1A1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040030155-A1 | Process for preparing active esters | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-02-12 | — | — | US | disclosed |
| EP-1350790-A1 | PROCESS FOR PREPARING ACTIVE ESTERS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-10-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040030155-A1 | Process for preparing active esters | CES1, CYP3A4, CYP3A5 | CYP2C19 14/4885SMN1; SMN2 3902/4885HSD17B10 123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.